Duzallo (allopurinol;lesinurad)
Additional monitoring
- Region
- 🇪🇺 EU
- Active substance
- allopurinol;lesinurad
- Company
- Grunenthal GmbH
- Status
- Withdrawn
- Therapeutic area
- Gout
- CHMP opinion
- Fri 28 Jun 2019
- EU approval
- Thu 23 Aug 2018
- Designations
- Additional monitoring
- Application
- EMEA/H/C/004412
- ATC
- M04AA51
- Official record
- www.ema.europa.eu
Indication
Duzallo is indicated in adults for the treatment of hyperuricaemia in gout patients who have not achieved target serum uric acid levels with an adequate dose of allopurinol alone.
Regulatory milestones
No milestones recorded in the last year.
Follow Duzallo
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.